CellCarta and Pillar Biosciences Form Strategic Partnership to Accelerate NGS Tumor Profiling for Oncology Trials
核心洞察
CellCarta (搜索) and Pillar Biosciences (搜索) announced a multi-year global strategic partnership to expand rapid, decentralized next-generation sequencing tumor profiling for oncology clinical trials worldwide.
The collaboration combines Pillar's oncoReveal (搜索) NGS kitted panels with CellCarta (搜索)'s global laboratory network to reduce screening friction, improve turnaround times, and support scalable companion diagnostic programs.
The partnership addresses growing challenges in biomarker-driven oncology trials, including pressure to enroll patients faster while managing tighter budgets and increasingly complex trial designs.
CellCarta (搜索), a global provider of precision medicine laboratory services for drug development, and Pillar Biosciences (搜索), a leader in NGS-based oncology molecular diagnostics, announced a global multi-year strategic partnership to broaden access to fast, operationally streamlined next-generation sequencing (NGS) tumor profiling for biopharma sponsors and clinical research partners worldwide.
The partnership pairs Pillar's portfolio of oncoReveal (搜索) kitted NGS panels with CellCarta (搜索)'s global laboratory network and biomarker expertise to reduce screening friction, improve turnaround time, reduce failure rates, and support scalable companion diagnostic programs.
Addressing Critical Industry Challenges
As oncology drug development becomes increasingly biomarker-driven, sponsors face mounting pressure to enroll patients faster while managing tighter budgets. Trial designs continue to fragment into smaller molecular subgroups, increasing screening volume, operational complexity, and the cost of delay. Testing strategies that rely on broad panels by default can add unnecessary time, expense, and friction when studies require a fit-for-purpose set of actionable markers.
This partnership is designed to remove that bottleneck by combining Pillar's portfolio of oncoReveal (搜索) NGS-based kitted panels with CellCarta (搜索)'s global clinical trial testing execution. Together, the companies will help sponsors right-size molecular testing to each study objective, reduce avoidable operational steps, and deliver actionable results on timelines that support enrollment and decision-making.
Streamlined Tumor Profiling Solutions
The collaboration will focus on enabling indication-relevant tumor profiling with reduced hands-on complexity, consistent performance expectations, and faster sample-to-report execution compared to traditional, more operationally burdensome approaches.
The partnership will help address sponsor cost pressure with fit-for-purpose profiling aligned to indication and trial objectives when broad panels are unnecessary and will support increasingly complex, biomarker-driven trial designs where turnaround time and reliability directly impact screen-fail rates and timelines.
"Biomarker-driven oncology trials demand testing strategies that are both operationally efficient and aligned with long-term development goals," said Robin Grimwood, SVP of Genomics at CellCarta (搜索). "Through our partnership with Pillar Biosciences (搜索), we combine their streamlined, rapid workflow with our global laboratory execution and deep CDx expertise to support faster enrollment and standardized implementation across regions. Importantly, this collaboration enables us to offer highly targeted, indication-specific panels for prospective testing, with the flexibility to develop custom panels aligned to sponsor programs — providing a consistent foundation for potential companion diagnostic alignment as assets advance."
Proprietary Technology Integration
Pillar's kitted NGS panels are based on the company's proprietary SLIMamp chemistry, designed to make high-value tumor profiling more operationally accessible to laboratories across the globe while still delivering actionable insights.
"Our kitted NGS panels, based on our proprietary SLIMamp chemistry, were designed to make high-value tumor profiling more operationally accessible to laboratories across the globe while still delivering actionable insights," said Dan Harma, Chief Commercial Officer at Pillar Biosciences (搜索). "By partnering with CellCarta (搜索), we can extend that value through a trusted global laboratory network and help sponsors deploy testing strategies that match today's realities: increasing trial complexity, tighter timelines, and more cost discipline."
Company Capabilities
CellCarta (搜索) operates as a leading global CRO laboratory to the biopharmaceutical industry, with CAP accreditations and CLIA certifications for specific testing methods and facilities in Canada, USA, Belgium, Australia, and China. The company provides a wide range of biomarker testing services and customized solutions to world-renowned pharmaceutical companies, integrating analytical platforms in immunology, histopathology, proteomics, and genomics, along with sample management and logistics services to support the entire drug development cycle from discovery to late-stage clinical trials.
Pillar Biosciences (搜索) serves as a global provider of next-generation sequencing kitted solutions designed to deliver high analytical performance and operational efficiency for cancer testing. Powered by proprietary SLIMamp and PiVAT technologies, Pillar enables localized testing to expand access to complex molecular diagnostics worldwide. The company offers a growing portfolio of IVD and RUO NGS kits targeting tumor profiling, biomarker analysis, and molecular research and monitoring applications.